The $30M cash infusion and HSR clearance significantly reduce deal risk and improve the pro forma balance sheet ahead of the Treeline merger. Monitor the stockholder vote and any competing bids; the merger is on track for year-end 2026 close.
Price Chart
Executive Summary
Standard BioTools announced the sale of its Mass Cytometry business to Multiplex Bio for up to $10M, received ~$30M from Illumina to buy out earnout/royalty obligations, and secured early HSR termination for its pending merger with Treeline Biosciences. These actions strengthen the balance sheet, reduce contingent liabilities, and de-risk the Treeline merger, which is expected to close by year-end 2026.
Key Financial Metrics
Key Facts
- Sale of Mass Cytometry business to Multiplex Bio for up to $10 million (seller's note + milestone payment)
- Received approximately $30 million from Illumina to buy out 2026 earnout and all future royalty payments related to the SomaLogic acquisition
- U.S. FTC granted early termination of HSR waiting period for the Treeline merger
- Treeline merger and Mass Cytometry sale expected to close by end of 2026, subject to stockholder approval and customary conditions
- Standard BioTools will provide Multiplex Bio with a working capital loan of up to $10 million at closing
Financial Impact
~$30M cash received from Illumina buyout; up to $10M from Mass Cytometry sale (seller's note + milestone); up to $10M working capital loan to Multiplex Bio
Risk Factors
- Stockholder approval required for both the Mass Cytometry sale and the Treeline merger
- Customary closing conditions may delay or prevent the transactions
- Potential for competing acquisition proposals or termination of the Treeline merger
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3334170 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 29, 2026 9w ago | 425 | $0.8739 $0.6518 | ▼ −25.41% | ▼ −30.43% | $0.7300 (−16.47%) |
Jul 28, 2026 9w ago | Press Release | $0.7947 $0.6500 | ▼ −18.21% | ▼ −21.59% | $0.7300 (−8.14%) |
Jul 20, 2026 10w ago | 425 | $0.8500 $0.6845 | ▼ −19.47% | ▼ −23.59% | $0.7300 (−14.12%) |
Jul 20, 2026 10w ago | S-4 | $0.8500 $0.6845 | ▼ −19.47% | ▼ −23.59% | $0.7300 (−14.12%) |
Jun 8, 2026 16w ago | 425 | $0.8032 $0.8873 | ▲ +10.47% | ▲ +8.84% | $0.7300 (−9.11%) |
Jun 8, 2026 16w ago | 8-K | $0.8032 $0.8873 | ▲ +10.47% | ▲ +8.84% | $0.7300 (−9.11%) |
Jun 8, 2026 16w ago | Press Release | $0.8032 $0.8873 | ▲ +10.47% | ▲ +8.84% | $0.7300 (−9.11%) |
Apr 24, 2026 23w ago | 8-K | $0.9000 $1.09 | ▼ −21.11% | ▼ −16.15% | $0.7300 (+18.89%) |
Apr 21, 2026 23w ago | Press Release | $0.9600 $0.9900 | ▲ +3.13% | ▼ −1.79% | $0.7300 (−23.96%) |
Feb 24, 2026 31w ago | 8-K | $1.17 $0.9600 | ▲ +17.95% | ▲ +12.71% | $0.7300 (+37.61%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access